Post-Myocardial Infarction Heart Failure

Bahit, María Cecilia; Kochar, Ajar; Granger, Christopher B.

doi:10.1016/j.jchf.2017.09.015

Cited by 283 publications

(246 citation statements)

References 40 publications

Supporting

Mentioning

212

Contrasting

Unclassified

Order By: Relevance

“…This finding is similar to those seen by Jeger et al and Shah et al where heart failure was the most common cardiac readmission diagnosis in a similar study population . Heart failure is a common sequela after AMI‐CS, and its incidence post AMI has been estimated to range from 14% to 36% . Evidence suggests that infarct size is directly related to mortality and development of heart failure .…”

Section: Discussionsupporting

confidence: 90%

“…10,30 Heart failure is a common sequela after AMI-CS, and its incidence post AMI has been estimated to range from 14% to 36%. 34 Evidence suggests that infarct size is directly related to mortality and development of heart failure. 35 Patients developing cardiogenic shock lost at least 40% of myocardium acutely or in combination with previous infarcts.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Frequency of 30‐day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock

Atti

Patel

Kumar

et al. 2019

Cathet Cardio Intervent

View full text Add to dashboard Cite

Background Survival after percutaneous coronary intervention (PCI) in acute myocardial infarction complicated by cardiogenic shock (AMI‐CS) has increased over the years. Short‐term readmission rates in this high‐risk population remain unknown. Methods We queried the United States (U.S.) Nationwide Readmission Database (NRD) from January 2010 to November 2014 using the International Classification of Diseases‐Ninth edition, Clinical Modification (ICD‐9 CM) codes to identify all patients ≥18 years readmitted within 30 days after surviving an index hospitalization for PCI in AMI‐CS. Incidence, etiologies, and predictors of 30‐day readmission were analyzed. Results Among 46,435 patients who survived to discharge after PCI in AMI‐CS, 9,020 (19.4%) were readmitted within 30 days. Median time to 30‐day readmission was 11 days. Cardiac conditions were the most common causes of readmission (57.8%). Heart failure was the leading readmission diagnosis (24.8%). Private insurance including HMO and self‐pay were predictive of lower 30‐day readmission. Among other covariates, female sex, comorbidities such as heart failure, atrial fibrillation, in‐hospital complications such as major bleeding, sepsis, respiratory complications, AKI requiring dialysis, utilization of mechanical circulatory support (IABP and ECMO) were independently predictive of 30‐day readmission. Trend analysis showed decline in 30‐day readmission rates from 21.9% in 2010 to 17.9% in 2014 (ptrend < 0.001). Conclusion In this large real‐world database, one in five patients receiving PCI in AMI‐CS was readmitted within 30 days after discharge. Cardiac conditions were the most common causes of readmission. Insurance type had significant influence on 30‐day readmission.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Frequency of 30‐day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock

Atti

Patel

Kumar

et al. 2019

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…2 However, survivors of MI have an increased risk of developing heart failure and have high rates of early post-discharge death and re-hospitalization. [3][4][5] While mortality from coronary artery disease has declined, heart failure has emerged as a leading public health burden worldwide. 4,6 Ischemia associated cardiomyopathy following a myocardial event is characterized by CM loss and failure of myocardial regeneration.…”

Section: Introductionmentioning

confidence: 99%

Isolation of cardiomyocytes undergoing mitosis with complete cytokinesis

Milliron

Weiland

Kort

et al. 2019

Preprint

View full text Add to dashboard Cite

Rationale-Adult human cardiomyocytes (CMs) do not complete cytokinesis despite passing through the S-phase of the cell cycle. As a result polyploidization and multinucleation occur. In order to get a deeper understanding of the mechanisms surrounding division of CMs there is a crucial need for a technique to isolate CMs that complete cell division/cytokinesis.Objective-Markers of cell cycle progression based on DNA content cannot distinguish between mitotic CMs that fail to complete cytokinesis from those cells that undergo true cell division. With the use of molecular beacons (MB) targeting specific mRNAs we aimed to identify truly proliferative CMs derived from hiPSCs.Methods and Results-Fluorescence activated cell-sorting combined with molecular beacons was performed to sort CM populations enriched for mitotic cells. Expressions of cell-cycle specific genes were confirmed by means of RT-qPCR, single-cell RNA sequencing (scRNA-seq). We further characterized the sorted groups by proliferation assays and time-lapse microscopy which confirmed the proliferative advantage of MB-positive cell populations relative to MB-negative and G2/M populations. Gene expression analysis revealed that the MB-positive CM subpopulation exhibited patterns consistent with the biological processes of nuclear division, chromosome segregation, and transition from M to G1 phase. The use of dual-MBs targeting CDC20 and SPG20 mRNAs (CDC20 + SPG20 + ) enabled the enrichment of cytokinetic events. Interestingly, cells that did not complete cytokinesis and remained binucleated were found to be CDC20 -SPG20 + while polyploid CMs that replicated DNA but failed to complete karyokinesis were found to be CDC20 -SPG20 -.Conclusions-This study demonstrates a novel alternative to existing DNA content-based approaches for sorting CMs with true mitotic potential that can be used to study in detail the unique dynamics of CM nuclei during mitosis. Together with high-throughput scRNA-seq, our technique for sorting live CMs undergoing cytokinesis would provide a basis for future studies to uncover mechanisms underlying the development and regeneration of heart tissue.

show abstract

“…However, STEMI survivors are at risk of developing heart failure (HF) — a disease exhibiting 50% mortality rates within 5 years of diagnosis . Adverse cardiac remodeling is one of the major risk factors for the development of post‐myocardial infarction (MI) HF, and patients suffering from post‐MI HF exhibit higher mortality and rehospitalization rates . Adverse cardiac remodeling can be defined as a 20% increase in end‐diastolic volume over 1 year compared with baseline values and is characterized by cardiomyocyte hypertrophy, interstitial fibrosis, loss of chamber geometry, and left ventricular dysfunction (LVD) .…”

mentioning

confidence: 99%

“…2 Adverse cardiac remodeling is one of the major risk factors for the development of post-myocardial infarction (MI) HF, and patients suffering from post-MI HF exhibit higher mortality and rehospitalization rates. 3 Adverse cardiac remodeling can be defined as a 20% increase in end-diastolic volume over 1 year compared with baseline values 4 and is characterized by cardiomyocyte hypertrophy, interstitial fibrosis, loss of chamber geometry, and left ventricular dysfunction (LVD). 5 Despite advanced interventional and pharmacological treatment options, up to one-third of patients develop adverse cardiac remodeling after MI.…”

mentioning

confidence: 99%

Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial

Düngen

Køber

Nodari

et al. 2018

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

The chymase inhibitor fulacimstat is developed as a first‐in‐class treatment option for the inhibition of adverse cardiac remodeling in patients with left ventricular dysfunction (LVD) after acute myocardial infarction (MI). The aim of the study was to examine the safety and tolerability of fulacimstat in patients with LVD after remote MI. A multicenter, multinational randomized, placebo‐controlled study was performed in clinically stable patients (40–79 years of age, left ventricular ejection fraction ≤ 45% because of MI in medical history) who were on stable evidence‐based standard‐of‐care therapies for LVD post‐MI including an angiotensin converting enzyme inhibitor or angiotensin receptor blocker at doses of at least half the recommended target dose. Patients were treated for 2 weeks with either placebo (n = 12) or 4 different doses of fulacimstat (5 mg twice daily, n = 9; 10 mg twice daily, n = 9; 25 mg twice daily, n = 10; 50 mg once daily, n = 9). Fulacimstat was safe and well tolerated at all examined doses. There were no clinically relevant effects on vital signs or potassium levels compared with placebo treatment. Mean plasma concentrations of fulacimstat increased with the administered dose and reached exposures predicted to be therapeutically active. The safety profile and the absence of effects on blood pressure or heart rate in a chronic patient population having similar comorbidities and receiving similar comedication as patients after acute MI support future clinical trials with fulacimstat in patients after acute MI.

show abstract

Post-Myocardial Infarction Heart Failure

Cited by 283 publications

References 40 publications

Frequency of 30‐day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock

Frequency of 30‐day readmission and its causes after percutaneous coronary intervention in acute myocardial infarction complicated by cardiogenic shock

Isolation of cardiomyocytes undergoing mitosis with complete cytokinesis

Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial

Contact Info

Product

Resources

About